TY - JOUR
T1 - Toward the cholinesterase inhibition potential of TADDOL derivatives
T2 - Seminal biological and computational studies
AU - Constantino, Andrea R.
AU - Charbe, Nitin
AU - Duarte, Yorley
AU - Gutiérrez, Margarita
AU - Giordano, Ady
AU - Prasher, Parteek
AU - Dua, Kamal
AU - Mandolesi, Sandra
AU - Zacconi, Flavia C.
N1 - Publisher Copyright:
© 2022 Deutsche Pharmazeutische Gesellschaft.
PY - 2022
Y1 - 2022
N2 - Alzheimer's disease (AD) is a degenerative neurological disease characterized by gradual loss of cognitive skills and memory. The exact pathogenesis involved still remains unrevealed, but several studies indicate the involvement of an array of different enzymes, underlining the multifactorial character of the disease. Inhibition of these enzymes is therefore a powerful approach in the development of AD treatments, with promising candidates, including acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and monoamine oxidase. Interestingly, AChE is the target of a major pesticide family (organophosphates), with several reports indicating an intersection between the pesticide's activity and AD. In this study, various TADDOL derivatives were synthesized and their in vitro activities as AChE/BuChE inhibitors as well as their antioxidant activities were studied. Molecular modeling studies revealed the capability of TADDOL derivatives to bind to AChE and induce inhibition, especially compounds 2b and 3c furnishing IC50 values of 36.78 ± 8.97 and 59.23 ± 5.31 µM, respectively. Experimental biological activities and molecular modeling studies clearly demonstrate that TADDOL derivatives with specific stereochemistry have an interesting potential for the design of potent AChE inhibitors. The encouraging results for compounds 2b and 3c indicate them as promising scaffolds for selective and potent AChE inhibitors.
AB - Alzheimer's disease (AD) is a degenerative neurological disease characterized by gradual loss of cognitive skills and memory. The exact pathogenesis involved still remains unrevealed, but several studies indicate the involvement of an array of different enzymes, underlining the multifactorial character of the disease. Inhibition of these enzymes is therefore a powerful approach in the development of AD treatments, with promising candidates, including acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and monoamine oxidase. Interestingly, AChE is the target of a major pesticide family (organophosphates), with several reports indicating an intersection between the pesticide's activity and AD. In this study, various TADDOL derivatives were synthesized and their in vitro activities as AChE/BuChE inhibitors as well as their antioxidant activities were studied. Molecular modeling studies revealed the capability of TADDOL derivatives to bind to AChE and induce inhibition, especially compounds 2b and 3c furnishing IC50 values of 36.78 ± 8.97 and 59.23 ± 5.31 µM, respectively. Experimental biological activities and molecular modeling studies clearly demonstrate that TADDOL derivatives with specific stereochemistry have an interesting potential for the design of potent AChE inhibitors. The encouraging results for compounds 2b and 3c indicate them as promising scaffolds for selective and potent AChE inhibitors.
KW - acetylcholinesterase inhibitors
KW - C symmetry
KW - molecular modeling analysis
KW - selective AChE inhibitors
KW - TADDOL derivatives
UR - http://www.scopus.com/inward/record.url?scp=85134772207&partnerID=8YFLogxK
U2 - 10.1002/ardp.202200142
DO - 10.1002/ardp.202200142
M3 - Article
AN - SCOPUS:85134772207
SN - 0365-6233
JO - Archiv der Pharmazie
JF - Archiv der Pharmazie
ER -